Filtered By:
Condition: Bleeding
Management: Health Insurance

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 71 results found since Jan 2013.

Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: A real-world nationwide cohort study
ConclusionsIn Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation, rivaroxaban may be associated with a similar risk of major bleeding but a lower risk of thromboembolism compared with warfarin. The potential benefit of 10 mg of rivaroxaban in this population requires further investigation.
Source: PLoS One - April 8, 2021 Category: Biomedical Science Authors: Yi-Cheng Lin Source Type: research

Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation
ConclusionsFor patients whose HAS-BLED scores increased to  ≥ 3, the continuation of OACs was associated with better clinical outcomes. An increased HAS-BLED score in anticoagulated AF patients may not be the only reason to withhold OACs, but reminds physicians to correct modifiable bleeding risk factors and follow up patients more closely.Graphical abstractAssociations between Continuation or Discontinuation of Oral Anticoagulants and Risks of Clinical Outcomes after HAS-BLED Scores IncreasedAF atrial fibrillation;aHR adjusted hazard ratio;ICH intra-cranial hemorrhage;OACs oral anticoagulants
Source: Clinical Research in Cardiology - January 1, 2022 Category: Cardiology Source Type: research

Clinical Outcomes of Drug-Eluting Stents vs. Bare-Metal Stents in Acute Myocardial Infarction Patients Under Dialysis　- A Nationwide Cohort Study.
CONCLUSIONS: Among AMI patients on dialysis undergoing percutaneous coronary interventions, DES implantation significantly reduced the risk of recurrent MI, CV death and all-cause mortality compared with BMS implantation. PMID: 26581755 [PubMed - as supplied by publisher]
Source: Circulation Journal - November 19, 2015 Category: Cardiology Authors: Chen DY, Mao CT, Tsai ML, Hsieh MJ, Lin YS, Cherng WJ, Wen MS, Wang CH, Hsieh IC, Hung MJ, Chen CC, Chen TH Tags: Circ J Source Type: research

Thromboembolic, Bleeding, and Mortality  Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation
BackgroundIt is unclear whether the non –vitamin K antagonist oral anticoagulant agents rivaroxaban and dabigatran are superior to warfarin for efficacy and safety outcomes in Asians with nonvalvular atrial fibrillation (NVAF).ObjectivesThe aim of this study was to compare the risk for thromboembolic events, bleeding, and mortality associated with rivaroxaban and dabigatran versus warfarin in Asians with NVAF.MethodsA nationwide retrospective cohort study was conducted of consecutive patients with NVAF taking rivaroxaban (n  = 3,916), dabigatran (n = 5,921), or warfarin (n = 5,251) using data collected from the Taiwan...
Source: Journal of the American College of Cardiology - September 20, 2016 Category: Cardiology Source Type: research

Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
CONCLUSIONS: Our findings support that the clinical effectiveness of extended DAPT in a hemodialysis population may be tempered after 6 months post-DES implantation. PMID: 28174317 [PubMed - in process]
Source: Clinical Journal of the American Society of Nephrology : CJASN - February 6, 2017 Category: Urology & Nephrology Authors: Chen YT, Chen HT, Hsu CY, Chao PW, Kuo SC, Ou SM, Shih CJ Tags: Clin J Am Soc Nephrol Source Type: research

The risk of lower gastrointestinal bleeding in low ‐dose aspirin users
ConclusionsThe risk of LGIB was higher in low‐dose aspirin users than in aspirin nonusers in this nationwide cohort. Low‐dose aspirin, NSAIDs, steroids, SSRIs, PPIs and H2RAs were independent risk factors for LGIB.
Source: Alimentary Pharmacology and Therapeutics - April 27, 2017 Category: Drugs & Pharmacology Authors: W. ‐C. Chen, K.‐H. Lin, Y.‐T. Huang, T.‐J. Tsai, W.‐C. Sun, S.‐K. Chuah, D.‐C. Wu, P.‐I. Hsu Tags: Original Article Source Type: research

The Use Pattern and Clinical Impact of New Antiplatelet Agents Including Prasugrel and Ticagrelor on 30-day Outcomes after Acute Myocardial Infarction in Korea: Korean Health Insurance Review and Assessment Data.
CONCLUSION: The use of new antiplatelet agents is rapidly increasing, and they have been used more commonly than clopidogrel since 2015. We demonstrated that new antiplatelet agents have a favorable effect on reducing 30-day mortality in AMI patients in Korea. PMID: 29035430 [PubMed - as supplied by publisher]
Source: Korean Circulation Journal - October 18, 2017 Category: Cardiology Tags: Korean Circ J Source Type: research

Cardiovascular and Bleeding Risks in Acute Myocardial Infarction Newly Treated With Ticagrelor vs. Clopidogrel in Taiwan.
CONCLUSIONS: In real-world AMI Taiwanese patients, ticagrelor seemed to offer better anti-ischemic protection than clopidogrel, without an increase in the rate of major bleeding. A large-scale randomized trial is needed to assess the efficacy and safety of ticagrelor in East Asian AMI patients. PMID: 29081474 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 27, 2017 Category: Cardiology Authors: Lee CH, Cheng CL, Kao Yang YH, Chao TH, Chen JY, Li YH Tags: Circ J Source Type: research

Health Care Costs and Utilization of Dabigatran Compared With Warfarin for Secondary Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Retrospective Population Study
Conclusions: The use of dabigatran is associated with lower emergency department and all-cause hospitalization costs but greater outpatient costs in a real-world, NVAF patient population compared with warfarin.
Source: Medical Care - April 12, 2018 Category: Health Management Tags: Original Articles Source Type: research

Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort.
CONCLUSION: Dual antiplatelet or triple therapy increased the risk of VH significantly, compared to warfarin monotherapy. Considering the low efficacy of preventing ischemic stroke and high risk of bleeding, dual or triple therapy using warfarin and antiplatelet agents should be avoided to prevent VH in AF patients. PMID: 30554492 [PubMed - in process]
Source: Yonsei Medical Journal - December 18, 2018 Category: Universities & Medical Training Authors: Kim KE, Yang PS, Jang E, Kim S, Joung B Tags: Yonsei Med J Source Type: research

Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health.
CONCLUSION: This study demonstrated the value of supplementing longitudinal site-based clinical studies with administrative claims data. Our results suggest that claims data together with network partner electronic health record data constitute an effective vehicle to capture patient outcomes since >30% of patients have non-fatal and fatal events outside of enrolling sites. PMID: 31081367 [PubMed - as supplied by publisher]
Source: Clinical Trials - May 12, 2019 Category: Research Authors: Ma Q, Chung H, Shambhu S, Roe M, Cziraky M, Jones WS, Haynes K Tags: Clin Trials Source Type: research

Major ischaemic and bleeding risks following current drug-eluting stent implantation: Are there differences across current drug-eluting stent types in real life?
CONCLUSIONS: In real life, major ischaemic and bleeding risks do not differ across the various c-DESs over the first year following implantation. Future studies are needed to assess comparative c-DES effectiveness and safety longer term. PMID: 31262635 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - June 27, 2019 Category: Cardiology Authors: Schapiro-Dufour E, Tricotel A, Slama MS, Ducimetière P, Trinh-Duc A, Sichel C, Le Tri T, Galmiche H, Dray-Spira R, Zureik M Tags: Arch Cardiovasc Dis Source Type: research

Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation Who Are Indicated for Standard Dosing
With safety concerns about increasing bleeding, off-label underdosing of non-vitamin K antagonist anticoagulants (NOACs) is common in East Asian patients with atrial fibrillation (AF). We tried to investigate the pattern of NOAC underdosing and associated clinical outcomes in patients with AF who are indicated for standard dosing. Using the Korean National Health Insurance Service database, we evaluated 16568 patients with a new prescription of NOAC who are indicated for standard NOAC dosing and compared 4536 patients with warfarin with respect to thromboembolic events (ischemic stroke or systemic embolization), all-cause ...
Source: The American Journal of Cardiology - February 6, 2020 Category: Cardiology Authors: Min Soo Cho, Ji Eun Yun, Ji Jeong Park, Yun Jung Kim, Jessie Lee, Hyungmin Kim, Duk-Woo Park, Gi-Byoung Nam Source Type: research

Oral Anticoagulants and Antiplatelet Agents in Atrial Fibrillation Patients with Concomitant Critical Limb Ischemia: A nationwide cohort study
ConclusionsDOAC was associated with a significantly lower risk of composite net-clinical-benefit outcome than either warfarin or APT in AF patients with concomitant CLI. Further prospective study is necessary to validate the findings in the future.
Source: Canadian Journal of Cardiology - February 19, 2020 Category: Cardiology Source Type: research

Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study
Conclusion: In cancer patients with AF, NOAC were associated with significant reduced IS/SE, major bleeding, and ICH compared to warfarin.
Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Victor Chien-Chia Wu, Chun-Li Wang, Yu-Tung Huang, Wen-Ching Lan, Michael Wu, Chang-Fu Kuo, Shao-Wei Chen, Pao-Hsien Chu, Ming-Shien Wen, Chi-Ching Kuo, Shang-Hung Chang Tags: Research Paper Source Type: research